RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
iKang Healthcare, a private China healthcare chain, completed a $1.4 billion privatization backed by an Alibaba investment arm and Yunfeng Capital, a private equity firm co-founded by Alibaba’s Jack Ma and David Yu. The company, which seems likely to become part of Alibaba Health, offers check-ups and disease screening. The privatization was completed at a price of $20.60 per ADS. iKang staged a $153 million IPO in 2014 and proposed a privatization 16 months later. It has taken three and a half years to complete the transaction.
Source: China Biotoday
